Tumor Biology

, Volume 36, Issue 2, pp 921–928 | Cite as

Mir-152 inhibits cell proliferation and colony formation of CD133+ liver cancer stem cells by targeting KIT

  • Haili Huang
  • Min Hu
  • Peng Li
  • Caijie Lu
  • Mingyi LiEmail author
Research Article


miR152 is involved in diverse biological functions and development of disease. This study investigates the role of mir-152 in cell proliferation and colony formation of liver cancer stem cells. We show that exogenous overexpression of mir-152 suppresses cell proliferation and colony formation in CD133+ hep3B cells. We also show that KIT is a direct target of miR-152 and miR-152 downregulates protein expression of KIT by directly binding to 3′ untranslated region of KIT. Downregulation of KIT by specific siRNAs inhibits proliferation and colony formation of CD133+ hep3B cells, which is similar to inhibitory effects of miR-152. Moreover, exogenous expression of KIT compromises inhibitory effects of miR-152 on cell proliferation and colony formation. Our findings suggest that mir-152 inhibits cell proliferation and colony formation of CD133+ hep3B cells by targeting KIT.


miR-152 KIT Liver cancer stem cells Proliferation 



The present study was supported by grants from the Science and Technology Program of Guangdong Province (2008B030301028) and the Science and Technology Innovation Fund of Guangdong Medical College (STI F201107).

Conflicts of interest


Supplementary material

13277_2014_2719_MOESM1_ESM.docx (18 kb)
ESM 1 (DOCX 18 kb)
13277_2014_2719_MOESM2_ESM.doc (28 kb)
Table S1 (DOC 28 kb)
13277_2014_2719_MOESM3_ESM.docx (62 kb)
Figure S1 (DOCX 62 kb)
13277_2014_2719_MOESM4_ESM.docx (277 kb)
Figure S2 (DOCX 277 kb)


  1. 1.
    Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109(4):542–53. doi: 10.1038/ajg.2014.11.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, et al. Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev. 2013;14(12):7251–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen WQ, Zheng RS, Zhang SW. Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 2013;32(4):162–9. doi: 10.5732/cjc.013.10027.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Matsuda T, Saika K. Trends in liver cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol. 2012;42(4):360–1. doi: 10.1093/jjco/hys048.CrossRefPubMedGoogle Scholar
  5. 5.
    Coviello E, Caputi G, Martinelli D, Germinario CA, Prato R. Mortality trends for primary liver cancer in Puglia. Italy Eur J Cancer Prev. 2010;19(6):417–23. doi: 10.1097/CEJ.0b013e32833ad36e.CrossRefPubMedGoogle Scholar
  6. 6.
    Chiba T, Kamiya A, Yokosuka O, Iwama A. Cancer stem cells in hepatocellular carcinoma: recent progress and perspective. Cancer Lett. 2009;286(2):145–53. doi: 10.1016/j.canlet.2009.04.027.CrossRefPubMedGoogle Scholar
  7. 7.
    Sukowati CH, Rosso N, Croce LS, Tiribelli C. Hepatic cancer stem cells and drug resistance: relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol. 2010;2(3):114–26. doi: 10.4254/wjh.v2.i3.114.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Sukowati CH, Tiribelli C. The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. Expert Rev Gastroenterol Hepatol. 2013;7(8):749–57. doi: 10.1586/17474124.2013.846826.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee TK, Cheung VC, Ng IO. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett. 2013;338(1):101–9. doi: 10.1016/j.canlet.2012.05.001.CrossRefPubMedGoogle Scholar
  10. 10.
    Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One. 2013;8(7):e70010. doi: 10.1371/journal.pone.0070010.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31(28):3357–69. doi: 10.1038/onc.2011.500.CrossRefPubMedGoogle Scholar
  12. 12.
    Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58(2):629–41. doi: 10.1002/hep.26369.CrossRefPubMedGoogle Scholar
  13. 13.
    Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene. 2011;30(31):3416–28. doi: 10.1038/onc.2011.62.CrossRefPubMedGoogle Scholar
  14. 14.
    Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, et al. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene. 2013. doi: 10.1038/onc.2013.478.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010;7(6):694–707. doi: 10.1016/j.stem.2010.11.010.CrossRefPubMedGoogle Scholar
  16. 16.
    Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8):e6816. doi: 10.1371/journal.pone.0006816.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29(29):4194–204. doi: 10.1038/onc.2010.167.CrossRefPubMedGoogle Scholar
  18. 18.
    Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52(1):60–70. doi: 10.1002/hep.23660.CrossRefPubMedGoogle Scholar
  19. 19.
    Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 2011;71(20):6450–62. doi: 10.1158/0008-5472.CAN-11-0364.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang YS, Chou WW, Chen KC, Cheng HY, Lin RT, Juo SH. MicroRNA-152 mediates DNMT1-regulated DNA methylation in the estrogen receptor alpha gene. PLoS One. 2012;7(1):e30635. doi: 10.1371/journal.pone.0030635.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Zheng X, Chopp M, Lu Y, Buller B, Jiang F. MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett. 2013;329(2):146–54. doi: 10.1016/j.canlet.2012.10.026.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, et al. miR-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. Prostate. 2013;73(10):1082–9. doi: 10.1002/pros.22656.CrossRefPubMedGoogle Scholar
  23. 23.
    Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444–50. doi: 10.1002/ijc.22476.CrossRefPubMedGoogle Scholar
  24. 24.
    Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–56. doi: 10.1053/j.gastro.2007.04.025.CrossRefPubMedGoogle Scholar
  25. 25.
    Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351(4):820–4. doi: 10.1016/j.bbrc.2006.10.128.CrossRefPubMedGoogle Scholar
  26. 26.
    Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012;315(2):129–37. doi: 10.1016/j.canlet.2011.10.012.CrossRefPubMedGoogle Scholar
  27. 27.
    Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z, et al. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol Cancer. 2014;13(1):86. doi: 10.1186/1476-4598-13-86.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, et al. MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology. 2010;52(5):1731–40. doi: 10.1002/hep.23904.CrossRefPubMedGoogle Scholar
  29. 29.
    Liu X, Zhan Z, Xu L, Ma F, Li D, Guo Z, et al. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIalpha. J Immunol. 2010;185(12):7244–51. doi: 10.4049/jimmunol.1001573.CrossRefPubMedGoogle Scholar
  30. 30.
    Muto S, Katsuki M, Horie S. Decreased c-kit function inhibits enhanced skin carcinogenesis in c-Ha-ras protooncogene transgenic mice. Cancer Sci. 2007;98(10):1549–56. doi: 10.1111/j.1349-7006.2007.00577.x.CrossRefPubMedGoogle Scholar
  31. 31.
    Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, Funahashi H, et al. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer. 2006;5:46. doi: 10.1186/1476-4598-5-46.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Gavert N, Shvab A, Sheffer M, Ben-Shmuel A, Haase G, Bakos E, et al. c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis. Cancer Res. 2013;73(18):5754–63. doi: 10.1158/0008-5472.CAN-13-0576.CrossRefPubMedGoogle Scholar
  33. 33.
    Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, et al. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia. 2008;10(9):996–1003.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene. 2013;32(22):2767–81. doi: 10.1038/onc.2012.290.CrossRefPubMedGoogle Scholar
  35. 35.
    Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013;4(9):1399–415.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li S, et al. MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT. Tumour Biol. 2013. doi: 10.1007/s13277-013-1551-z.Google Scholar
  37. 37.
    Gao XN, Lin J, Gao L, Li YH, Wang LL, Yu L. MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk Res. 2011;35(9):1226–32. doi: 10.1016/j.leukres.2011.06.010.CrossRefPubMedGoogle Scholar
  38. 38.
    Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, van Ijcken WF, Wozniak A, et al. MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. Br J Cancer. 2013;109(6):1625–35. doi: 10.1038/bjc.2013.483.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM, et al. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res. 2011;17(24):7584–94. doi: 10.1158/1078-0432.CCR-11-0166.CrossRefPubMedGoogle Scholar
  40. 40.
    Koelz M, Lense J, Wrba F, Scheffler M, Dienes HP, Odenthal M. Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. Int J Oncol. 2011;38(2):503–11. doi: 10.3892/ijo.2010.857.CrossRefPubMedGoogle Scholar
  41. 41.
    Li P, Ma L, Zhang Y, Ji F, Jin F. MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation. Biomed Pharmacother. 2014;68(1):7–12. doi: 10.1016/j.biopha.2013.12.002.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Haili Huang
    • 1
  • Min Hu
    • 2
  • Peng Li
    • 1
  • Caijie Lu
    • 2
  • Mingyi Li
    • 2
    Email author
  1. 1.Clinical Research Centerthe Affiliated Hospital of Guangdong Medical CollegeZhanjiangChina
  2. 2.Department of Hepatobiliary Surgerythe Affiliated Hospital of Guangdong Medical CollegeZhanjiangChina

Personalised recommendations